Active Ingredient
salicylic acid 2%
Beisitian Facial Bump Refining Essence Liquid
FDA Label NDC 87786-053
Full FDA labeling including Indications, Dosage, Usage, and Precautions
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Wenzhou Yuyuan Pharmaceutical Co., Ltd. for the product Beisitian Facial Bump Refining Essence (NDC 87786-053). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient, purpose, uses, warnings, do not use, when using, stop use, ask doctor, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Purpose
Skin Papule Refining
Uses
Aids in smoothing skin texture through gentle exfoliation.
Warnings
For external use only. Stop using and consult a doctor if rash or irritation occurs.
Avoid contact with eyes, ears, mouth and broken skin.
Do Not Use
On children under 2 years of age.
On open skin wounds.
When Using
Keep product away from eyes, ears, mouth and broken skin.
Stop Use
Discontinue use and consult a doctor if persistent irritation or rash develops.
Ask Doctor
Discontinue use and consult a doctor if persistent irritation or rash develops.
Keep Out Of Reach Of Children
Keep out of the reach of children.
If swallowed, seek medical help or contact a Poison Control Center immediately.
Directions
Apply twice daily after cleansing and toning. Use for at least 4 weeks.
Dispense a pea‑sized amount of the essence onto problematic areas and massage with fingertips until fully absorbed.
Other Information
In case of eye contact, rinse thoroughly with clean water.
Store in a cool, dry place.
Inactive Ingredients
Water, Niacinamide, Camellia Sinensis Leaf Extract, Dextrin, Xanthan Gum, Amylopectin, Tocopheryl Acetate.
Principal Display Panel
2 (Ae01d85ada80bc34ee073a5f03cb658c)
* Please review the disclaimer below.
